Document:

EX-10.19

 Exhibit 10.19 
  

					
		 		  	 ***Text Omitted and Filed Separately

with the Securities and Exchange Commission

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 230.406

 Internal University Use Only 

OTC Agreement No.: 

OTC Docket No.(s): Z09079 

Document Revision Date: 05/11/2009 - Final 

UNIVERSITY OF MINNESOTA 

EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (the “Agreement”) is made by and between Regents of the University of
Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. 

Purpose 

The University and the Licensee are joint owners of the Licensed Technology, as that term is defined and used in this
Agreement. The Licensee desires that the University grant it an exclusive license under the University’s interest in the Licensed Technology to use, develop, and commercialize the inventions claimed in the Licensed Technology, The University is
willing to grant such a license on the terms set forth below. 
 NOW, THEREFORE, the parties agree that: 

The Terms and Conditions of Exclusive Patent License attached hereto as Exhibit A are incorporated herein by reference in
their entirety (the “Terms and Conditions”). In the event of a conflict between provisions of this Agreement and the Terms and Conditions, the provisions in this Agreement shall govern. Capitalized terms used in this Agreement without
definition shall have the meanings given to them in the Terms and Conditions. 
 The section numbers used in the parentheses
below correspond to the section numbers in the Terms and Conditions. 
 1. Licensee (1.11). Celladon Corporation, a California
corporation, having a place of business at 2223 Avenida de la Playa, Suite 300, La Jolla, CA 92037. 
 2. Field(s) of Use
(1.6). Pharmaceutical screening and testing for human and animal application. 
 3. Territory (1.17). The territory
is any country or territory where an active and enforceable Licensed Patent or a Patent Application exists. 
 4. Effective
Date. The effective date is the date of the last signature of this Agreement. 

  
 1. 

 5. Licensed Technology. 

5.1 Licensed Patents(s) (1.9). As of the Effective Date, there are no issued Licensed Patents. 

5.2 Patent Application(s) (1.12). The following Patent Application exists as of the Effective Date: 

 

							
	 Application
No.
	  	 Country
	  	 Filing Date
	  	 Title

	 [...***...]
	  	United States	  	[...***...]	  	[...***...]

 6. Patent-Related Expenses (1.13). 

The Licensee shall have the first right to prepare, file and prosecute the Patent Applications and maintain the Licensed
Patents pursuant to Section 4 of the Terms and Conditions, at the Licensee’s sole expense. Accordingly, Licensee shall be responsible for paying directly to the appropriate parties all such Patent Related Expenses Licensee incurs in
connection therewith. 
 7. Sublicense Rights (3.1.2). Select one of the following: 

x    Yes 

 ̈    No 

8. Federal Government Rights (3.2). Select one of the following: 

x    Yes 

 ̈    No 

9. Performance Milestones (5.1). Performance Milestones are as follows: 

Within 24 months from the Effective Date, Licensee shall have entered into a written agreement with a third party under which
the Licensee, using the Licensed Technology, screens or tests or causes to be screened or tested potential biological or pharmaceutical materials as drug candidates for subsequent pre-clinical and clinical development; provided, however, that in the
event of a Change of Control of Licensee that occurs within 24 months from the Effective Date, Licensee’s successor-in-interest need not enter into any such third party agreements but shall be obligated to use the Licensed Technology to screen
or test or cause to be screened or tested potential biological or pharmaceutical materials as drug candidates for subsequent pre-clinical and clinical development within 24 months from the Effective Date. 

***Confidential Treatment Requested 

  
 2. 

 Within 60 months from the Effective Date, a third party must have agreed in
writing to undertake pre-clinical and clinical development on a drug candidate identified by Licensee or a sublicensee using the Licensed Technology; provided, however, that in the event of a Change of Control of Licensee that occurs within
60 months from the Effective Date, Licensee’s successor-in-interest need not obtain the written agreement of another third party but shall be obligated to undertake pre-clinical and clinical development on a drug candidate identified by
Licensee, Licensee’s successor or a sublicense using the Licensed Technology within 60 months from the Effective Date. 
 10.
Progress Reports (5.4). Progress Reports are due every six months, with the first report due on six months after the Effective Date and subsequent reports due every six months thereafter. 

11. Payments (6.1). All amounts are non-refundable, and payable as defined below or as specified in the University’s invoice.

 11.1 Upfront Payment. Upfront Payment in the amount of One Hundred Twenty Thousand and 00/100 dollars
($120,000), due within 10 days after the Effective Date. 
 11.2 Annual License Fee. The Annual
License Fee is due on each anniversary of the Effective Date. The initial amount of the Annual License Fee is One Hundred Twenty Thousand and 00/100 dollars ($120,000) (“Initial Amount”). The Initial Amount will increase to Three
Hundred Twenty Five Thousand and 00/100 dollars ($325,000) (“Increased Amount”) upon the occurrence of the first to occur of any of the events listed below (“Triggering Event”). Licensee shall notify the University immediately
upon the first occurrence of a Triggering Event. 
 Triggering Events 

(i) A Change of Control occurs, whether by agreement or operation of law; 

(ii) The Agreement, any rights and obligations contained in the Agreement, or the Licensee’s joint ownership interest in
the Invention(s), Licensed Patents or Patent Applications, are assigned, conveyed, or otherwise transferred (excluding by license), whether by agreement or operation of law, to an Affiliate under Section 14B of the Terms and Conditions,
excluding any such assignment, conveyance or transfer to an Affiliate that is a wholly-owned subsidiary of the Licensee or that is under common control (as defined in Section 1.1 of the Terms and Conditions) with the Licensee (in which case,
the term “Triggering Event” shall encompass any of the events described clauses (i), (iii), (iv), (v) and (vi) of this section 11.2 that occurs with respect to such Affiliate, mutatis mutandis); 

  
 3. 

 (iii) The Agreement, any rights and obligations contained in the Agreement, or
the Licensee’s joint ownership interest in the Invention(s), Licensed Patents or Patent Applications, are assigned, conveyed, or otherwise transferred (excluding by license), whether by agreement or operation of law, to a third party; 

(iv) Licensee has received cumulative License Revenues (defined below) from any and all licenses and sublicenses granted by
Licensee (whether exclusive or non-exclusive) and/or Service Revenues (defined below) from any and all Affiliates and third parties, of at least [...***...]. 

For purposes of this clause (iv), “License Revenues” means all amounts actually received by Licensee from Affiliates
and third parties arising from the grant of a license or sublicense under the Licensed Patents and Patent Applications, including upfront fees, technology access fees, {sub)license fees, annual maintenance fees, premiums above the fair market value
on sales of debt or equity securities of Licensee, and any other payments in respect of a license or sublicense of the Licensed Patents and Patent Applications; provided, however, that License Revenues shall exclude: (a) royalties on
sales of Identified Products; (b) payments for debt or equity securities of Licensee (other than premiums above the fair market value of such securities as of the date of such payments); and (c) reimbursements of patent costs actually
incurred by Licensee; and “Service Revenues” means all amounts actually received by Licensee from Affiliates and third parties in consideration of the use by Licensee (or a third party contractor on behalf of Licensee) of the Licensed
Technology to screen such Affiliates’ and third parties’ compounds or materials for the purpose of identifying or developing Identified Products; 

(v) An investigational new drug application, new drug application, biologic license application or orphan drug application (or
any foreign equivalent of such applications) is filed by Licensee, its Affiliate or a third party licensee of Licensee or its Affiliate for an Identified Product (whether such Identified Product is a drug or biologic); or 

(vi) Licensee enters into any agreement, partnership, joint venture, or other relationship with a third party to market or use
the Licensed Technology (except for use of the Licensed Technology to perform assay services solely on behalf of Licensee under (iv)). 
 If
a Triggering Event occurs on any day other than the anniversary of the Effective Date, Licensee shall pay to University within 30 days of the Triggering Event an additional amount equal to the difference (calculated on a pro rata basis), between the
Initial Amount and the Increased Amount for the 12-month period in which the Triggering Event occurred. 
 ***Confidential Treatment Requested 

  
 4. 

 For example, if the Effective Date of this Agreement is April 1, 2009, and no Triggering
Event occurs prior to the first anniversary of the Effective Date (April 1, 2010), then the Annual License Fee due on April 1, 2010, would be $120,000. If a Triggering Event occurs three months later on July 1, 2010, then the Annual
Maintenance Fee due on the following anniversary of the Effective Date (April 1, 2011) and continuing throughout the Term of the Agreement would be $325,000. Additionally to compensate the University for the nine-month period beginning on the date
of the Triggering Event (July 1, 2010) and ending on the following anniversary of the Effective Date (April 1, 2011), Licensee would pay to the University an additional $153,750, which would represent a pro rata adjustment of the Annual License Fee
for the nine months remaining before the next anniversary of the Effective Date, calculated as follows: 
 0.75 x ($325,000
– $120,000), i.e., 0.75 x $205,000, equals $153,750 
 11.3 Intentionally Deleted. 

11.4 Intentionally Deleted. 

11.5 Interest Rate (6.2). The Interest Rate will be [...***...] percent ([...***...]%) per annum. 

11.6 Other. None. 

12. Licensee’s Address for Notice (23). Notices will be sent to the Licensee at: 

Celladon Corporation 

Attn: Chief Executive Officer 

c/o Enterprise Partners Venture Capital 

2223 Avenida de la Playa 

Suite 300 

La Jolla, CA 92037 

Facsimile No.: 858-731-0231 

Email: [...***...]@celladon.net 

13. Licensee expressly warrants and represents and does hereby state and represent that no promise or agreement which is not herein
expressed has been made to Licensee in executing this Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying upon any statement or representation of the University or their
representatives. 
 14. Licensee is relying on Licensee’s own judgment and has been represented by legal counsel. Said
legal counsel has read and explained to Licensee the entire contents of this Agreement and the Terms and Conditions incorporated by reference herein. Licensee hereby warrants and represents that the Licensee understands and agrees to all the
provisions in this Agreement and said Terms and Conditions. 
 ***Confidential
Treatment Requested 

  
 5. 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this Agreement. 
  

									
	 Regents of the University of Minnesota
	  		  	 Celladon Corporation

					
	 By:
	 	 /s/ Jay W. Schrankler
	  		  	 By:
	  	 /s/ Krisztina M. Zsebo

		 	 Jay W. Schrankler

Executive Director
 Office for
Technology Commercialization
	  		  	 Name:

Title:
	  	 Krisztina M. Zsebo, Ph.D.

Chief Executive Officer

			
	 Date: 5-11-09
	  		  	 Date: 5/11/09

  
 6. 

 Internal University Use Only 

OTC Agreement No.: 

OTC Docket No.(s): Z09079 

Document Revision Date: 05/11/2009 - Final 

UNIVERSITY OF MINNESOTA 

EXHIBIT A 
 Terms and
Conditions 
 Exclusive Patent License Agreement 

These terms and conditions to the Exclusive Patent License Agreement (“Terms and Conditions”) govern the grant of
license by Regents of the University of Minnesota (“University”) to the Licensee identified in the Exclusive Patent License Agreement (the “EPLA”). These Terms and Conditions are incorporated by reference into the EPLA. All
section references in these Terms and Conditions refer to provisions in these Terms and Conditions unless explicitly stated otherwise. 

1. Definitions. For purposes of interpreting the Agreement, the following terms have the following meanings: 

1.0 “Active Claim” means a claim of (a) an issued and unexpired Licensed Patent which has not been held
unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction in a ruling that is unappealed or unappealable, or (b) a pending Patent Application that has not been pending for more than ten
(10) years from the date of the priority date of the Patent Application. If a claim of a pending Patent Application that ceased to be an Active Claim under clause (b) of the preceding sentence because of the passage of time later issues as
part of a Licensed Patent within clause (a) of the preceding sentence, then it shall again be considered an Active Claim effective as of the issuance of such Licensed Patent. 

1.1 “Affiliate” means an entity which, directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with Licensee, but only for so long as such relationship exists. The term “control,” as used in the immediately preceding sentence means the beneficial ownership of more than 50% of the shares of
the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority). 

1.2 “Agreement” means collectively these Terms and Conditions and the EPLA. 

1.3 “Change of Control” means: 

(i) any consolidation or merger of the Licensee with or into any other corporation or other entity, or any other corporate
reorganization, excluding (x) any transaction effected exclusively to change the domicile of the Licensee, (y) any consolidation, merger or reorganization in which the stockholders of the Licensee immediately prior to such consolidation,
merger or reorganization, continue to hold at least a majority of the voting power of the surviving entity (if the surviving entity is a wholly-owned subsidiary, its parent) in 

  
 A-1 

 
substantially the same proportions as were held immediately after such consolidation, merger or reorganization, and (z) a consolidation with a wholly-owned subsidiary of the Licensee; 

(ii) any transaction or series of related transactions to which the Licensee is a party in which in excess of 50% of
Licensee’s voting power is transferred, other than a transaction or series of related transactions with arm’s-length financial investors (e.g., venture capital firms), consummated for bona fide equity financing purposes, in
which cash is received by the Licensee or indebtedness of the Licensee is cancelled or converted, or a combination thereof; 

(iii) a sale of all or substantially all of the Licensee’s assets; or 

(iv) a transaction of any type in which the power to direct or cause the direction of the management or polices of Licensee is
transferred to any person, persons, entity or entities, none of which, as of the Effective Date possesses such power. For purposes of clarification, this paragraph (iv) is not intended, and shall not be construed, to cover changes in
composition of the Licensee’s board of directors resulting from director resignations, removals, appointments, or elections occurring in the ordinary course and not in consideration or as a result of either of the following: {a) any transaction
or series of transactions under Section 1.3(ii) above, or (b) the license, sale or transfer to a third party of any right with respect to the Invention(s), the Licensed Patents or the Patent Applications. 

1.4 “Commercially Reasonable Efforts” means, with respect to Licensee’s efforts to accomplish a particular
objective with respect to development and exploitation of the Invention(s), such reasonable and good faith efforts to accomplish such objective as are consistent with the efforts biopharmaceutical companies (defined below) typically devote to
invention(s) or other technology of similar market potential and at a similar stage of development as the Invention(s). For purposes of this definition, “biopharmaceutical companies” means companies in the biopharmaceutical industry of a
size and stage of development similar to that of Licensee. 
 1.5 “EPLA” means the Exclusive Patent License
Agreement to which these Terms and Conditions are attached as Exhibit A. 
 1.6 “Field of Use” means the field(s)
of use described in section 2 of the EPLA. 
 1.7 “Identified Product” means any product or good in the Field of
Use that is identified, or the utility of which is identified, using any Licensed Technology during the Term; excluding any such product or good that itself constitutes Licensed Technology. The term Identified Product refers only to products and
goods identified, manufactured, made, sold, transferred, or otherwise disposed of during the Term. 
 1.8
“Invention(s)” means the invention(s) expressly disclosed in that certain Invention Disclosure No. No. [...***...], entitled “[...***...], including, without limitation, the
inventions claimed in the pending patent application(s) described in section 5.2 of the EPLA. 
 ***Confidential Treatment Requested 

  
 A-2 

 1.9 “Licensed Patent” means: (a) the patent(s) described in
section 5.1 of the EPLA (if any); (b) all patents that issue from any Patent Application or that contain one or more claims directed to Invention(s); and (c) all reissues, reexaminations, renewals, and extensions of any patent referenced
in the preceding clauses (a) and (b). 
 1.10 “Licensed Technology” means any product, method or process, the
manufacture, use or sale of which is covered by one or more Active Claims of a Licensed Patent or Patent Application in the country of such manufacture, use or sale. 

1.11 “Licensee” means the entity identified in section 1 of the EPLA. 

1.12 “Patent Applications” means: (a) all patent applications filed, or that may be filed in the future,
claiming any Invention(s), including, without limitation, the pending patent application described in section 5.2 of the EPLA; (b) all foreign patent applications associated with (by priority claim or otherwise) the application(s) referenced in
the preceding clause (a), whether now existing or hereafter filed; and (c) all continuations, continuations-in-part, substitutions, and divisionals of the patent applications referenced in the preceding clauses (a) and (b). 

1.13 “Patent-Related Expenses” means costs and expenses (including out-of-pocket attorneys’ fees, patent agent
fees and governmental filing fees) incurred in preparing, filing and prosecuting the Patent Applications, and maintaining the Licensed Patents. 

1.14 “Payment” means a payment to be made by the Licensee to the University specified below in section 6.1 and
described in section 11 of the EPLA. 
 1.15 “Performance Milestone” means an act or event specified below in
section 5.1 and described in section 9 of the EPLA. 
 1.16 “Post-termination Period” means the one hundred eighty
(180) day period commencing on the date of termination (but not expiration) of the Term. 
 1.17 “Territory”
means the geographical area described in section 3 of the EPLA. 
 2. Term. The term of the Agreement commences on the Effective Date
as defined in section 4 of the EPLA and, unless terminated earlier as provided below in section 8, expires on the date on which no Active Claim of any Licensed Patent or Patent Application exists in the Territory (the “Term”). 

3. Grant of License. 

3.1 The Licensee’s Rights. For the avoidance of doubt, and notwithstanding any other provision of the Agreement to
the contrary, the University acknowledges and agrees that: (i) the University and the Licensee are joint owners of the Invention(s), the Licensed Patents and the Patent Applications; (ii) at all times during and after the Term, the
Licensee has the right to 

  
 A-3 

 
practice the Invention(s), and to grant licenses to practice the Invention(s) under Licensee’s joint ownership interest in the Licensed Patents and the Patent Applications, without the
University’s consent and, except as set forth in section 11.2 of the EPLA during the Term, without accounting to the University; and (iii) the purpose of this Agreement is to grant the Licensee an exclusive license under the
University’s joint ownership interest in the Invention(s), the Licensed Patents and the Patent Applications. 

3.1.1 Subject to the terms and conditions of this Agreement, the University hereby grants to the Licensee, and
the Licensee hereby accepts, an exclusive license under University’s interest in the Licensed Patents and the Patent Applications, to practice the Invention(s) in the Field of Use in the Territory, including, without limitation, to make
(including to have made on its behalf), use, offer to sell, sell or have sold, offer to lease or lease, import, or otherwise offer to dispose or dispose of any Licensed Technology in the Field of Use (including for the purpose of identifying and
developing Identified Products) in the Territory. Subject to the first paragraph of this section 3.1, no provision of the Agreement is to be construed to grant the Licensee, by implication, estoppel or otherwise, any rights (other than the rights
expressly granted it in the Agreement) to the Invention(s), a Licensed Patent or Patent Application, or to any other University-owned technology, patent applications, or patents. 

3.1.2 The Licensee shall have the right to sublicense its rights under the University’s interest in the
Invention(s), the Licensed Patents and the Patent Applications to its Affiliates and to third parties. If the Licensee grants any such sublicense, then the Licensee shall deliver to the University a true, correct, and complete copy of the
fully-executed sublicense agreement within 30 days after execution, provided that the Licensee may redact from such copies any proprietary scientific or business information that is not necessary to ascertain the Licensee’s compliance with the
Agreement. Each such sublicense shall expressly state that it is subject in all respects to the applicable provisions of the Agreement and shall not contain any term or condition that is inconsistent with the terms of the Agreement, including
without limitation, sections 5.2 - 5.6, 6.3, 8.3, 9.5, and 11.3. Any sublicense attempted to be made or made in violation of this subsection is void and constitutes an event of default under subsection 8.1.1 below. 

3.2 The United States Government’s Rights. If the University indicated in section 8 of the EPLA that the United
States federal government funded the development, in whole or in part, of the Invention(s), then, (i) the federal government may have certain rights in and to the Invention(s) as those rights are described in Chapter 18, Title 35 of the United
States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal Regulations, and (ii) the parties’ rights and obligations with respect to the Invention(s), including the grant of license set forth above in
subsection 3.1.1, are subject to the applicable terms of these laws and regulations. 
 3.3 The University’s
Rights. The University retains an irrevocable, world-wide, royalty-free, non-exclusive right (a) to use the Invention(s) for teaching, non-commercial research, and educational purposes and (b) the right to grant non-exclusive licenses
to other nonprofit or academic institutions to use the Invention(s) solely for teaching, non-commercial 

  
 A-4 

 research, and educational purposes. For the avoidance of doubt, the performance on behalf of, or
in collaboration with, a for-profit entity of sponsored research or other services using the Invention(s) does not constitute non-commercial research. Notwithstanding the foregoing, the University shall at all times have the right to use the
Invention(s) for the purpose of performing sponsored research on behalf of the Licensee and its Affiliates. 
 4. Applications and
Patents. 
 4.1 Patent Application Filings during the Term of the Agreement. 

4.1.1 The Licensee shall have the first right to prepare, file and prosecute the Patent Applications and to
maintain the Licensed Patents, at Licensee’s expense. After consultation with and approval (not to be unreasonably withheld or delayed) by the University, the Licensee shall determine in which countries patent application(s) will be filed and
prosecuted with respect to the Invention(s), provided that if the University fails to respond within 30 days after the Licensee informs the University that it wishes to file in such country, then the Licensee shall be free to proceed with such
filing without the University’s approval. The Licensee shall retain counsel reasonably acceptable to the University to file and prosecute such patent applications. The Licensee shall consult with the University as to the preparation, filing and
prosecution of the Patent Applications and the maintenance of the Licensed Patents reasonably prior to any deadline or action with the U.S. Patent & Trademark Office or any foreign patent office, and shall furnish to the University copies
of all relevant documents reasonably in advance of such deadline or action; provided, however, that if the University does not provide comments to the Licensee regarding any such filing or other patent office action within 30 days
after the Licensee provides a draft of such filing or notice of such proposed action to the University, then the Licensee shall be free to proceed with such filing or other action. The University shall be solely responsible for the fees and costs of
its own patent counsel. The Licensee shall keep the University informed of the status of the Licensee’s patent preparation, filing, prosecution and maintenance activities, including delivering to the Licensee pertinent notices, written and oral
communications with governmental officials, and documents. The Licensee shall also cause its counsel to copy the University on all correspondence (including attachments and enclosures) that pertain to the preparation, filing, prosecution, and
maintenance of the Patent Application and Licensed Patent. In the event that the Licensee desires to abandon any Patent Application or Licensed Patent, or if Licensee later declines responsibility for any Patent Application or Licensed Patent,
Licensee shall provide reasonable prior written notice to the University of such intention to abandon or decline responsibility (which notice shall, in any event, be given no later than 60 days prior to the next deadline for any action that may be
taken with respect to such Patent Application or Licensed Patent with the U.S. Patent & Trademark Office or any foreign patent office), and the University shall have the right, at its expense, to assume responsibility for the preparation,
filing prosecution and maintenance of the applicable Patent Application or Licensed Patent. 
 4.1.2 The
grant of license in section 3.1 and the definition of Territory in section 1.17 shall not extend to or include any country in which Licensee elects, in 

  
 A-5 

 
writing to the University, not to pay or reimburse the payment of the cost, in whole or in part, to seek or maintain intellectual property protection. 

4.2 Ownership of the Licensed Patents and Patent Applications. Neither the provisions of the Agreement, nor any
termination or expiration of this Agreement, shall affect the Licensee’s joint ownership interest in the Licensed Patents or Patent Applications in any manner. 

5. Commercialization. 

5.1 Commercialization and Performance Milestones. The Licensee shall use its Commercially Reasonable Efforts, consistent
with sound and reasonable business practices and judgment, to develop and commercially exploit the Invention(s) as soon as practicable. In furtherance of the objective set forth in the preceding sentence, the Licensee shall perform, or to cause to
happen or be performed, as the case may be, all the performance milestones described in section 9 of the EPLA. The University acknowledges that pharmaceutical development and regulatory approval process is inherently uncertain and involves high
risks of failure, and that many factors beyond the reasonable control of Licensee may delay or prevent Licensee from achieving a performance milestone. Accordingly, the University agrees to consider in good faith any request by Licensee for an
extension of the deadline for the applicable performance milestone(s) if Licensee has used Commercially Reasonable Efforts to achieve such performance milestones, provided that, for purposes of this sentence only, the University shall have the right
to withhold its consent if University, in the exercise of its sole discretion, determines that Licensee has not used Commercially Reasonable Efforts to achieve such performance milestones. 

5.2 Covenants Regarding the Manufacture of Licensed Technology. The Licensee hereby covenants and agrees to manufacture,
use, sell, and transfer Licensed Technology and any Identified Products in compliance with all applicable federal and state laws, including all federal export laws and regulations. The Licensee hereby further covenants and agrees that, to the extent
required by 35 United States Code Section 204, it shall, and it shall cause each sublicensee, to substantially manufacture in the United States of America all products embodying or produced through the use of Licensed Technology that is subject
to the rights of the federal government of the United States of America. 
 5.3 Export and Regulatory Compliance. The
Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but
not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (i) ITAR and EAR product/service/data-specific
requirements; (ii) ITAR and EAR ultimate destination-specific requirements; (iii) ITAR and EAR end user-specific requirements; (iv) Foreign Corrupt Practices Act; and (v) antiboycott laws and regulations. The Licensee shall
comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Technology (including any associated products, items, articles,

  
 A-6 

 
computer software, media, services, technical data, and other information). The Licensee certifies that it shall not, directly or indirectly, export (including any deemed export), nor re-export
(including any deemed re-export) the Licensed Technology (including any associated products, items, articles, computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations or other
applicable U.S. laws and regulations. The Licensee shall include an appropriate provision in its agreements with its authorized sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and
other applicable U.S. laws and regulations. 
 5.4 Progress Reports. Throughout the Term, and within thirty
(30) days of the date specified in the schedule set forth in section 10 of the EPLA, the Licensee shall deliver to the University written reports of the Licensee’s and the sublicensees’ efforts and plans to (i) develop and
commercialize Licensed Technology and (ii) reach the Performance Milestones and the Triggering Events; provided that once a Triggering Event has occurred, progress reports concerning other Triggering Events are not required. 

5.5 Use of the University’s Name and Trademarks or the Names of University Faculty, Staff, or Students. No
provision of the Agreement grants the Licensee or sublicensee any right or license to use the name, logo, or any marks owned by or associated with the University or the names, or identities of any member of the faculty, staff, or student body of the
University. The Licensee shall not use and shall not permit a sublicensee to use any such logos, marks, names, or identities without the University’s and, as the case may be, such member’s prior written approval. Notwithstanding the
foregoing, the Licensee may state that the University is a joint owner of the Invention(s), Patent Applications and Licensed Patents, and that the Licensee has an exclusive license under the University’s interest therein, in financing
documents, in communications with investors, potential investors and potential sublicensees, in required securities filings, or as otherwise required by applicable law. 

5.6 Governmental Markings. 

5.6.1 If feasible, the Licensee shall mark all physical embodiments of Licensed Technology (including packaging
material) that Licensee sells or transfers to any third party with patent notice appropriate under Title 35, United States Code. 

5.6.2 The Licensee is responsible for obtaining all necessary governmental approvals for the production,
development, distribution, sale, and use of the Licensed Technology, at the Licensee’s expense. The Licensee is responsible for including with any physical embodiment of Licensed Technology that Licensee sells or transfers to any third party,
any relevant warning labels, packaging and instructions as to the use of the Licensed Technology. 
 5.6.3
The Licensee agrees to register the Agreement with any foreign governmental agency that requires such registration, and the Licensee shall pay all costs and legal fees in connection with such registration. The Licensee shall comply with all foreign
laws affecting the Agreement or the use or sale of the Licensed Technology. 

  
 A-7 

 6. Payments, Reimbursements, Reports, and Records. 

6.1 Payments. The Licensee shall pay all amounts due under the Agreement by check (payable to the “Regents of the
University of Minnesota” and sent to the address specified below in section 23), wire transfer, or any other mutually agreed-upon method of payment. 

6.2 Interest. All amounts due under the Agreement shall bear interest as provided in section 11 of the EPLA on the
entire unpaid balance computed from the due date until the amount is paid. 
 6.3 Inspection of Records. During the
Term and for one (1) year thereafter, University shall have the right to cause an independent, certified public accountant reasonably acceptable to Licensee to inspect: (a) any and all agreements to which Licensee is a party that relate to
the practice, use, license, sale or transfer of any Licensed Technology and associated documentation, solely for the purposes of ascertaining whether and when the first Triggering Event has occurred and whether and when the performance milestones
described in section 9 of the EPLA have been achieved; and (b) all Licensed Patent and Patent Application filings and other patent office submissions with respect thereto, all correspondence between the Licensee (or its patent counsel) and any
patent office relating to any Licensed Patent or Patent Application, and all other documentation relating to the prosecution of Patent Applications or the maintenance of Licensed Patents. Licensee shall have no obligation to provide access to any
information of Licensee’s other than that specified in the preceding sentence. Licensee may require such accountant to execute a reasonable written confidentiality agreement with Licensee as a condition to allowing such inspection. University
agrees that such accountant shall have the right to disclose to University only such information as is necessary to determine whether and when the first Triggering Event has occurred. Such inspection may be conducted during normal business hours
upon reasonable prior written notice to Licensee, provided that University shall not have the right to cause such inspection more than once per year. University shall bear the full cost of such inspection unless such inspection discloses that
Licensee failed to timely notify University of the first Triggering Event to occur, in which case, Licensee shall bear the full cost of such inspection and shall promptly remit to University the amount of any underpayment of annual license fees
resulting from failure to report such occurrence. 
 6.4 Currency and Checks. All payments made under the Agreement
shall be in United States dollars. All computations and payments made under the Agreement shall be in United States dollars. To determine the dollar value of transactions conducted in non-United States dollar currencies, the parties shall use the
exchange rate for the currency into dollars as reported in the Wall Street Journal as the New York foreign exchange mid-range rate on the last business day of the month in which the transaction occurred. 

7. Infringement. 

7.1 If a party learns of substantial, credible evidence that a third party is making, using, or selling a product in the Field
of Use in the Territory that infringes a Licensed Patent, such party shall promptly notify the other party in writing of the possible infringement and in such notice describe in detail (to the extent known) the information suggesting infringement of

  
 A-8 

 
the Licensed Patent. Prior to commencing any action to enforce a Licensed Patent, the parties shall consult with each other in good faith regarding the alleged infringement and potential
enforcement activity. The Licensee shall have the first right to bring and control any action or proceeding with respect to such infringement, at its own expense and by counsel of its own choice reasonably acceptable to the University. At the
request of the University, such counsel shall at Licensee’s expense represent the University in the event the University is joined as an indispensible party in such action, subject to any applicable rules of professional conduct. If the
Licensee fails to bring any such action or proceeding within 120 days following the notice of alleged infringement, then the University shall have the right to bring and control any such action at its own expense and by counsel of its own choice. If
a party brings any such infringement action pursuant to this section 7.1, the other party shall provide reasonable cooperation to the enforcing party at the enforcing party’s request and expense and shall use reasonable efforts to permit access
by the enforcing party to relevant personnel, records, papers, information, samples and specimens during regular business hours. 

7.2 If any suit, action or proceeding is brought or commenced against the Licensee alleging the infringement of a patent or
other intellectual property right owned by a third party by reason of the manufacture, use or sale of the Licensed Technology, the Licensee shall give the University prompt notice thereof. If any third party institutes any suit, action or proceeding
challenging the validity of a Licensed Patent, neither party shall have the right to make any settlement or compromise which affects the scope, validity, enforceability or otherwise the Licensed Patent without the other party’s prior written
approval. 
 8. Termination. 

8.1 By the University. 

8.1.1 If the Licensee breaches or fails to perform one or more of its obligations under the Agreement, the
University may deliver a written notice of default to the Licensee. Without further action by a party, the Agreement shall terminate if the default has not been cured in full within (x) thirty (30) days after the delivery to the Licensee
of the notice of default if the default relates to a payment or reimbursement obligation under this Agreement or (y) ninety (90) days after the delivery to the Licensee of the notice of default if the default relates to any other matter.

 8.1.2 The University may terminate the Agreement by delivering to the Licensee a written notice of
termination at least ten (10) days before the date of termination if the Licensee (i) is adjudicated insolvent; (ii) voluntarily files or has filed against it a petition under applicable bankruptcy or insolvency laws that the Licensee
fails to have released within thirty (30) days after filing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee, custodian, or similar agent is appointed; or (iv) makes a
general assignment for the benefit of creditors. 
 8.1.3 The University may terminate the Agreement
immediately by delivering to the Licensee a written notice of termination if the Licensee or its agents or 

  
 A-9 

 
representatives commences or maintains an action in any court of competent jurisdiction or a proceeding before any governmental agency asserting or alleging, in any respect, the invalidity or
unenforceability of any of the Licensed Patents or Patent Applications. 
 8.2 By the Licensee. The Licensee may
terminate this Agreement for any reason or for no reason upon ninety (90) days’ written notice to the University. 

8.3 Effect on Sublicenses. Any sublicense agreement that was in effect between Licensee and any Affiliate or third party
immediately prior to any termination of this Agreement shall survive as a license solely under Licensee’s joint ownership interest in the Invention(s), Licensed Patents and Patent Applications, and such Affiliate or third party shall have no
further right or license under University’s joint ownership interest in the Invention(s), Licensed Patents and Patent Applications (i.e., any exclusivity of such Affiliate’s or third party’s access or rights with respect to the
Invention(s), Licensed Patents and Patent Applications shall effectively terminate). 
 9. Release, Indemnification, and Insurance.

 9.1 The Licensee’s Release. For itself and its employees, the Licensee hereby releases the University and
its regents, employees, and agents forever from any and all suits, actions, claims, liabilities, demands, damages, losses, or expenses {including reasonable attorneys’ and investigative expenses) relating to or arising out of the
Licensee’s exercise or attempt to exercise any of the rights or licenses granted it under this Agreement, including, without limitation, the manufacture, use, lease, sale, or other disposition of the Licensed Technology or Identified Products,
and the Licensee’s breach of any term of this Agreement. 
 9.2 The Licensee’s Indemnification. Throughout
the Term and thereafter, the Licensee shall indemnify, defend, and hold the University and its regents, employees, and agents {each, a “University Indemnitee”) harmless from all suits, actions, claims, liabilities, demands, damages,
losses, or expenses, including reasonable attorneys’ and investigative expenses (collectively, “Losses”), with respect to any third party claim relating to or arising out of the Licensee’s exercise or attempt to exercise any of
the rights or licenses granted it under this Agreement, including, without limitation, the manufacture, use, lease, sale, or other disposition of the Licensed Technology or Identified Products, or the Licensee’s breach of any term of this
Agreement; except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any University Indemnitee or the University’s breach of any term of this Agreement. 

9.3 The University’s Indemnification. Subject to the Damage Cap set forth below in section 11.2, throughout the
Term and thereafter, the University shall indemnify, defend, and hold the Licensee and its directors, employees, and agents harmless from all Losses with respect to any third party claim relating to or arising out of the gross negligence or willful
misconduct of any University Indemnitee or the University’s breach of any term of this Agreement. 

  
 A-10 

 9.4 The Licensee’s Insurance. 

9.4.1 Throughout the Term, or during such other period as the parties agree in writing, the Licensee shall
maintain, and shall cause each sublicensee to maintain, in full force and effect comprehensive general liability (“CGL”) insurance, with commercially reasonable claim limits in light of the Licensee’s activities under this Agreement.
From and after the first commercial sale of any Licensed Technology by Licensee or a sublicensee, such insurance policy shall include coverage for claims by a third party against the Licensee or the University arising out of the purchase or use of
Licensed Technology. Such insurance policy must name the University as an additional insured if the University so requests in writing. Upon receipt of the University’s written request, the Licensee shall deliver to the University a copy of the
certificate of insurance for such policy. 
 9.4.2 The provisions of subsection 9.4.1 do not apply if the
University agrees in writing to accept the Licensee’s or a sublicensee’s, as the case may be, self-insurance plan as adequate insurance. 

9.5 Sublicensees - Release. The Licensee shall cause each sublicensee to grant the University a release from liabilities
substantially similar to the release granted in favor of the University above in section 9.1. 
 10. Warranties. 

10.1 Authority. Each party represents and warrants to the other party that it has full corporate power and authority to
execute, deliver, and perform the Agreement, and that no other corporate proceedings by such party are necessary to authorize the party’s execution or delivery of the Agreement. In addition, the University represents and warrants to the
Licensee that this Agreement does not conflict with any other agreement to which the University is a party as of the Effective Date of this Agreement, and that the University has not granted to any third party (other than as described in section
3.3) any license, option or other rights with respect to the University’s interest in the Invention(s), Patent Applications or Licensed Patents. 

10.2 Disclaimers. 

10.2.1 EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, EACH PARTY DISCLAIMS AND EXCLUDES ALL
WARRANTIES, EXPRESS AND IMPLIED, CONCERNING THE LICENSED TECHNOLOGY, EACH LICENSED PATENT, EACH PATENT APPLICATION, AND EACH IDENTIFIED PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT, OF MERCHANTABILITY AND OF FITNESS FOR A
PARTICULAR PURPOSE. 

  
 A-11 

 10.2.2 Each party expressly disclaims any warranties concerning
and makes no representations: 
  

	 	 (i)
	 that the Patent Applications will be allowed or granted or that a patent will issue from any Patent Application; 

 

	 	 (ii)
	 concerning the validity, interpretation of claims or scope of any Licensed Patent; or 

 

	 	 (iii)
	 that the exercise of the rights or licenses granted to the Licensee under the Agreement will not infringe a third party’s patent or violate
its intellectual property rights. 

 11. Damages. 

11.1 Remedy Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, IN NO EVENT SHALL EITHER PARTY BE
LIABLE FOR (A) PERSONAL INJURY OR PROPERTY DAMAGES (EXCEPT TO THE EXTENT OF SUCH PARTY’S WILLFUL, WANTON, OR INTENTIONAL ACTS) OR (B) LOST PROFITS, LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER
RELIANCE OR EXPECTANCY, DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND ARISING OUT OF THIS AGREEMENT; provided, however, that this section 11.1 shall not be construed to limit either party’s
indemnification obligations with respect to third party claims under sections 9.2 and 9.3. 
 11.2 Damage
Cap. EXCEPT IN THE CASE OF THE UNIVERSITY’S FRAUD OR WILLFUL MISCONDUCT, IN NO EVENT SHALL THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THE AGREEMENT EXCEED THE AMOUNT OF PAYMENTS PAID TO THE UNIVERSITY UNDER
SECTION 6.1 OF THE AGREEMENT. THIS LIMITATION APPLIES TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE. 
 11.3
Sublicensees - Damages. The Licensee shall cause each sublicensee to agree to limitations of remedies and damages substantially similar to the limitations of remedies and damages set forth above in sections 11.1 and 11.2. 

12. Amendment and Waiver. The Agreement may be amended from time to time only by a written instrument signed by the parties. No term or
provision of the Agreement may be waived and no breach excused unless such waiver or consent is in writing and signed by the party claimed to have waived or consented. No waiver of a breach is to be deemed a waiver of a different or subsequent
breach. 
 13. Assignment. Except as permitted under section 14 of these Terms and Conditions, the Licensee shall not assign
the Agreement or any of its rights and obligations hereunder without the University’s prior written consent. Any assignment attempted to be made in violation of this section is void. Absent the consent of all the parties, an assignment will not
release the assigning  

  
 A-12 

 
party from its obligations. The Agreement inures to the benefit of the Licensee and the University and their respective successors, permitted assigns and trustees. 

14. Change of Control and Assignment to Affiliate. 

A. Change of Control. Notwithstanding section 13 above, the Licensee may assign this Agreement and its
rights and obligations hereunder, without the consent or approval of the University, in connection with a Change of Control, 

B. Assignment to Affiliate. Notwithstanding section 13 above, the Licensee, without the prior approval of the
University, may assign all, but no less than all, its rights and delegate all its duties under the Agreement to an Affiliate if the Licensee delivers to the University written notice of the proposed assignment (along with pertinent information about
the terms of the assignment and assignee) at least ninety (90) days before the effective date of the assignment. 
 15.
Applicable Law. The internal laws of the state of Minnesota, without giving effect to its conflict of laws principles, govern the validity, construction, and enforceability of the Agreement. 

16. Access to University Information. 

16.1 Data Practices Act. The parties acknowledge that the University is subject to the terms and provisions of the
Minnesota Government Data Practices Act, Minnesota Statutes §13.01 et seq. (the “Act”), and that the Act requires, with certain exceptions, the University to permit the public to inspect and copy any information that the
University collects, creates, receives, maintains, or disseminates. 
 16.2 Limited Confidentiality. To the extent
permitted by law, including as provided in the Act, the University shall hold in confidence and disclose only to University employees, agents and contractors who need to know the information disclosed or made available by the Licensee to the
University pursuant to sections 4.1, 5.4, 6.3 and 7. No provision of the Agreement is to be construed to further prohibit, limit, or condition the University’s right to use and disclose any information in connection with enforcing the
Agreement, in court or elsewhere. 
 17. Consent and Approvals. Except as otherwise expressly provided, in order to be effective, all
consents or approvals required under the Agreement must be in writing. 
 18. Construction. The headings preceding and
labeling the sections of the Agreement are for the purpose of identification only and are not to be employed or used for the purpose of construction or interpretation of any portion of EPLA. As used herein and where necessary, the singular includes
the plural and vice versa, and masculine, feminine, and neuter expressions are interchangeable. 
 19. Enforceability. If a
court of competent jurisdiction adjudges a provision of the Agreement to be unenforceable, invalid, or void, such determination is not to be construed as  

  
 A-13 

 impairing the enforceability of any of the remaining provisions hereof and such provisions will
remain in full force and effect. 
 20. Entire Agreement. The parties intend the Agreement (including all attachments, exhibits, and
amendments hereto) to be the final and binding expression of their contract and agreement and the complete and exclusive statement of the terms thereof. The Agreement cancels, supersedes, and revokes all prior negotiations, representations and
agreements among the parties, whether oral or written, relating to the subject matter of the Agreement. 
 21. No Third-Party
Beneficiaries. No provision of the Agreement, express or implied, is intended to confer upon any person other than the parties to the Agreement any rights, remedies, obligations, or liabilities hereunder. No sublicensee may enforce or seek
damages under the Agreement. 
 22. Language. In order to be effective, all notices, reports, and other documents and
instruments that a party elects or is required to deliver to the other party must be in English. 
 23. Notices. In order to
be effective, all notices, requests, and other communications that a party is required or elects to deliver must be in writing and must be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a
recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid, return receipt requested, to the other party at its address set forth below or to such other address as such party may designate by
notice given under this section: 
  

			
	 If to the University:
	  	 University of Minnesota

Office for Technology Commercialization

Attn: Contracts Manager
 1000
Westgate Drive, Suite 160
 St. Paul, MN 55114

Phone: 612.624.0550
 Fax:
612.624.6554
 E-mail: [...***...]@umn.edu

Web site: http://www.research.umn.edu/techcomm

		
	 For notices sent
under section 8,
with a copy to:
	  	 University of Minnesota

Office of the General Counsel

Attn: Transactional Law Services

360 McNamara Alumni Center
 200
Oak Street S.E.
 Minneapolis, MN 55455-2006

Facsimile No.: 612.626.9624

E-mail: [...***...]@mail.ogc.umn.edu
  

	 If to the Licensee:
	  	 As indicated in section 12 of the EPLA.

 ***Confidential Treatment Requested 

  
 A-14 

 24. Publicity. Each party may disclose to the public the execution and delivery of the
Agreement along with the other party’s name and the title(s) of the Invention(s). 
 25. Relationship of Parties. In
entering into, and performing their duties under the Agreement, the parties are acting as independent contractors and independent employers. No provision of the Agreement creates or is to be construed as creating a partnership, joint venture, or
agency relationship between the parties. No party has the authority to act for or bind the other party in any respect. 
 26.
Security Interest. In no event may the Licensee grant, or permit any person to assert or perfect, a security interest in the Licensee’s rights under the Agreement or in University’s ownership interest in any Licensed Patent or Patent
Application. 
 27. Survival. Immediately upon the termination or expiration of the Agreement, the license granted to the
Licensee under the Agreement shall terminate. Neither termination nor expiration of the Agreement shall relieve either party from any obligations accrued to the date of such termination. The parties’ respective obligations and rights set forth
in sections 6.1, 9, 10.2, 11 through 23, 27 and 28 of these Terms and Conditions also survive the termination or expiration of the Agreement. 

28. Forum Selection. A suit, claim, or other action to enforce the terms of the Agreement may be brought only in the state courts of
Hennepin County, Minnesota. The Licensee hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over the Licensee or the subject matter of this Agreement. 

  
 A-15EX-10.20

 Exhibit 10.20 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 

NON-EXCLUSIVE LICENSE AGREEMENT 

THIS NON-EXCLUSIVE LICENSE
AGREEMENT (the “Agreement”) is entered into as of November 4, 2010 (the “Effective Date”), by and between CELLADON
CORPORATION, a California corporation (“Celladon”), having offices at 2223 Avenida de la Playa, Suite 205, La Jolla, California 92037, and VIROVEK
INCORPORATION, a California corporation (“Virovek”), having offices at 3521 Investment Boulevard, Suite 1, Hayward, CA 94545. 

WHEREAS, Virovek has developed and owns certain intellectual property, including the
Patent Rights and Trade Secrets; and 
 WHEREAS, Celladon wishes to obtain, and Virovek
is willing to grant, a non-exclusive, worldwide license under the Patent Rights and Trade Secrets to develop a Celladon In Vitro Screening Reagent (as defined below) to be commercialized as part of an
in vitro neutralizing antibody assay (“NAb Assay”) for use with Celladon Product (as defined below), on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and promises
hereinafter set forth, the parties hereto hereby agree as follows: 
 1. DEFINITIONS 

1.1 “Affiliate” shall mean any company or entity controlled by, controlling, or under common control with a
party hereto and shall include any company more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by a party, and any company which owns or controls, directly or indirectly, more than 50%
of the voting stock of a party. 
 1.2 “Celladon In Vitro Screening Reagent” shall mean an AAV1/GFP vector
reagent, the manufacture, use, sale, offer for sale or import of which, (a) in the absence of a license under the Patent Rights, would infringe at least one Valid Claim of the Patent Rights and/or (b) uses or otherwise incorporates the
Trade Secrets. 
 1.3 “Celladon Product” shall mean an adeno-associated virus with a SERCA2a transgene
(AAV1/SERCA2a) enzyme replacement therapy, including, without limitation, Celladon’s proprietary MYDICAR® product. 

1.4 “Confidential Information” shall have the meaning provided in Section 5.1. 

1.5 “Field” shall mean the performance of Tests to determine the suitability of patients for treatment with
Celladon Product. 
 1.6 “First Commercial Sale” shall mean the first sale of Services to a Third Party in
the Field by Celladon or its sublicensees. 
 1.7 “NAb Assay” shall have the meaning set forth in the
recitals. 

 1.8 “Patent Rights” shall mean: 

(a) the patents and patent applications listed on Exhibit A attached hereto and any patents or patent
applications filed or granted in the future, that are owned by or licensed to Virovek and which cover the composition, manufacture or use of an AAVI/GFP vector reagent using Virovek’s proprietary AAV baculovirus technology; 

(b) any and all divisionals, continuations and continuations-in-part of the patents and patent applications referenced
in the preceding subsection (a); 
 (c) the foreign patent applications associated with the patent applications
referenced in the preceding subsections (a) and (b); 
 (d) the patents issued or issuing from the patent
applications referenced in the preceding subsections (a) through (c); and 
 (e) reissues, reexaminations,
restorations (including supplemental protection certificates) and extensions of any patent or patent application referenced in the preceding subsections (a) through (d). 

1.9 “Royalty Term” shall have the meaning provided in Section 3.3. 

1.10 “Services” shall mean the performance of Tests. 

1.11 “Service Revenues” shall mean all up front, annual, milestone, royalty and other payments received by
Celladon based upon and as a result of the commercial sale of Services by Celladon, its Affiliates and its and their respective sublicensees to Third Parties. 

1.12 “Test” shall mean an in vitro test (including, without limitation, an NAb Assay) that
incorporates or otherwise uses Celladon In Vitro Screening Reagent. 
 1.13 “Third Party” shall mean any
entity other than Celladon or Virovek or an Affiliate of Celladon or Virovek. 
 1.14 “Valid Claim” shall
mean a claim of an issued and unexpired patent included within the Patent Rights, which claim has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is
not appealable or has not been appealed within the time allowed for appeal) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. 

1.15 “Virovek Recombinant Baculoviruses” shall mean the recombinant baculoviruses owned or controlled by
Virovek that may be used to manufacture AAV1/GFP vector reagents. 

 1.16 “Trade Secrets” shall mean the proprietary and/or
confidential compositions, articles, and methods including manufacturing expertise and know-how in possession of Virovek related to the production and/or use of the Virovek Recombinant Baculoviruses but not explicitly described in the Patent Rights.

 2. GRANT OF LICENSE 

2.1 License Grant. Subject to the terms and conditions of this Agreement, Virovek hereby grants to Celladon a
non-exclusive, royalty-bearing, worldwide license and sublicense, including the right to grant sublicenses through multiple tiers of sublicense, under the Patent Rights and Trade Secrets to make, have made, use, sell, have sold, offer for sale and
import Celladon In Vitro Screening Reagents for use in the Field. 
 2.2 Sublicensing. Celladon may grant
sublicenses under this Agreement only pursuant to a written sublicense agreement containing terms and conditions consistent with the terms and conditions of this Agreement. 

2.3 No Implied Licenses. No license, option or other right under any intellectual property rights of either party
is granted or shall be granted by implication. All such licenses, options or other rights are or shall be granted only as expressly provided in the terms of this Agreement. 

2.4 Manufacturing Transfer and Trade Secrets. Promptly following the Effective Date, Virovek shall use
commercially reasonable efforts to facilitate and assist in the transfer of the Virovek Recombinant Baculoviruses to Third Party contract organization(s) designated by Celladon. In connection with such transfer, Virovek shall also share and deliver
the Trade Secrets, including its manufacturing expertise and know-how, to Celladon and such Third Party contractor(s) to enable such Third Party contractor(s) to manufacture and test AAV1/GFP vector reagents, starting materials, and in-process
components. If Celladon determines that on-site expertise is required to enable the Third Party contractor(s) to manufacture the AAV1/GFP vector reagents, Celladon may request that a Virovek expert travel to Celladon’s or such Third Party
contractor’s site to provide assistance and know-how regarding the manufacture of AAV1/GFP vector reagents. Upon such request, Virovek shall use commercially reasonable efforts to make such expert available to Celladon as requested. In such
event, Celladon shall be responsible to pay for the reasonable and documented travel expenses of such expert in providing on-site services, including flights, lodging and meals. In addition, Celladon shall compensate Virovek at the rate of $[...***...] per hour (for a maximum of eight hours per day) for the performance of the requested services; provided that Celladon shall pay only 50% of such hourly fee for the travel time to and
from Celladon’s or such Third Party contractor’s site. Celladon shall be responsible: (a) to ensure that each such Third Party contractor is bound by confidentiality obligations with respect to the Trade Secrets at least as stringent
as those contained herein; and (b) for any breach of this Agreement by any of such Third Party contractors. 
 ***Confidential Treatment Requested 

 2.5 Diligence. Celladon shall use commercially reasonable efforts, either
itself or through its Affiliates or sublicensees, to develop and commercialize Tests in the Field. 
 2.6 Regulatory
Filings and Matters. Celladon shall be solely responsible for making all regulatory filings and seeking all regulatory approvals that Celladon determines in its sole discretion to be necessary or appropriate in connection with the development
and commercialization of Tests. 
 3. PAYMENT OBLIGATIONS 

3.1 License Fee. Celladon shall pay to Virovek a non-refundable license fee of
US$15,000 (the “License Fee”) on the Effective Date. 
 3.2 Maintenance Fees. Celladon shall pay to Virovek
an annual non-refundable maintenance fee of US$20,000 (the “Annual Maintenance Fees”) on each anniversary of the Effective Date during the term of this Agreement; provided that all Annual Maintenance Fees paid by
Celladon shall be fully creditable toward royalties due under Section 3.3 below. For the avoidance of doubt, by crediting the Annual Maintenance Fees toward royalties, Celladon shall be obligated to pay Virovek royalties as provided in
Section3.3 only to the extent such royalties during the calendar year in which the royalties were earned exceed the Annual Maintenance Fee. 

3.3 Royalties. Subject to Sections 3.2 and 3.4, during the Royalty Term Celladon shall pay to Virovek [...***...] % of Service Revenues; provided that if, during the Royalty Term, the manufacture, use, sale, offer for sale or import of AAV1/GFP vector reagent used in the Tests is no longer
covered by at least one Valid Claim of the Patent Rights or by at least one claim of a pending patent application included within the Patent Rights, the royalties payable under this Section 3.3 shall be reduced to [...***...] % of Service
Revenues. Royalties under this Section 3.3 shall be paid, on a Test-by-Test and country-by-country basis: (a) in the case of any Services using a Test covered by a Valid Claim of the Patent Rights in any country, the period of time from
First Commercial Sale of Services using a Test in a country until the expiration of the last-to-expire Valid Claim of the Patent Rights claiming the manufacture, use, sale, offer for sale or import of Celladon In Vitro Screening Reagent used in such
Test in such country; and (b) in the case of any Services using a Test covered solely by Trade Secrets in any country, the period of time commencing on the First Commercial Sale in such country and ending 10 years from the date of First
Commercial Sale in such country (the “Royalty Term”). 
 3.4 Third Party Licenses. In the
event that Celladon or its Affiliates or sublicensees are required to obtain one or more licenses under patents of Third Parties that, in the absence of such license(s), would be infringed by the manufacture, use, sale, offer for sale or import of a
Test, the percentage royalty payment due to Virovek under Section 3.3 shall be reduced by 50%. 
 4. PAYMENTS;
RECORDS; AUDITS 
 4.1 Payment; Reports. Royalty payments and reports of Service
Revenues shall be calculated and reported for each calendar quarter. All royalty payments due to Virovek under this Agreement shall be paid within 60 days of the end of each calendar quarter. Each payment 

***Confidential Treatment Requested 

 of royalties shall be accompanied by a report of Service Revenues in sufficient detail to permit
confirmation of the accuracy of the royalty payments made, including, without limitation, the identity of the sublicensees selling the Services, the gross sales and net sales of the Services, the royalties payable and the method used to calculate
the royalty. 
 4.2 Exchange Rate; Manner and Place of Payment. All payments hereunder shall be payable in U.S.
dollars. With respect to each quarter, for countries other than the United States, whenever conversion of royalty payments from any foreign currency shall be required, such conversion shall be made at the rate of exchange reported in The Wall
Street Journal on the last business day of such quarter. All payments owed under this Agreement shall be made by wire transfer to a bank and account designated in writing by Virovek, unless otherwise specified in writing by Virovek. 

4.3 Taxes. Virovek will pay any and all taxes levied on account of any payments made to it under this Agreement.
If any taxes are required to be withheld by Celladon, Celladon will (a) deduct such taxes from the payment made to Virovek, (b) timely pay the taxes to the proper taxing authority, and (c) send proof of payment to Virovek and certify
its receipt by the taxing authority within 30 days following such payment. 
 4.4 Records and Audits.
Celladon shall keep for a period covering at least the preceding two years complete and accurate records pertaining to receipt of Service Revenues in sufficient detail to permit Virovek to confirm the accuracy of the royalty payments made hereunder.
Virovek shall have the right to cause an independent, certified public accountant reasonably acceptable to Celladon to audit such records for a period covering not more than the preceding two years for the purpose of verifying any amounts payable
under this Agreement. Such audits may be exercised during normal business hours upon reasonable prior written notice to Celladon. Prompt adjustments shall be made by the parties to reflect the results of such audit. Virovek shall bear the full cost
of such audit, unless such audit discloses a variance of more than 10% from the amounts actually due, in which case Celladon shall bear the full cost of such audit. 

5. CONFIDENTIALITY 

5.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
parties, the parties agree that, during the term of this Agreement and for five years thereafter, each party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for
in this Agreement any information furnished to it by the other party pursuant to this Agreement (collectively, “Confidential Information”). Each party may use Confidential Information of the other party only to
the extent required to accomplish the purposes of this Agreement. Each party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its employees, agents, consultants and
other representatives do not disclose or make any unauthorized use of the other party’s Confidential Information, which standard of care shall be not less than reasonable care. Each party will promptly notify the other upon discovery of any
unauthorized use or disclosure of the other party’s Confidential Information. 

 5.2 Exceptions. Confidential Information of a party (the
“disclosing party”) shall not include any information which the other party (the “receiving party”) can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to
act on the part of the receiving party in breach of this Agreement, generally known or available; (b) is known by the receiving party at the time of receiving such information, as evidenced by its previously-existing written records;
(c) is hereafter furnished to the receiving party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the receiving party without the use of Confidential
Information belonging to the disclosing party. 
 5.3 Authorized Disclosure. The receiving party may disclose
Confidential Information to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or defending litigation or complying with applicable governmental regulations, provided that if the receiving
party is required to make any such disclosure of the Confidential Information, it will to the extent practicable give reasonable advance notice to the disclosing party of such disclosure requirement and, except to the extent inappropriate in the
case of patent applications, will cooperate with the disclosing party’s efforts to secure confidential treatment of such information required to be disclosed at the request and expense of the disclosing party. 

6. PATENT RIGHTS 

6.1 Filing, Prosecution and Maintenance of the Patent Rights. Virovek shall have the sole right to file,
prosecute and maintain the Patent Rights, at Virovek’s sole expense. During the term of this Agreement, Virovek shall take all commercially reasonable actions necessary to file, defend, prosecute and maintain the Patent Rights. In the event
that Virovek desires to abandon, or to cease the diligent prosecution, maintenance and/or defense of, any Patent Right, Virovek shall provide reasonable prior written notice to Celladon of such intention to abandon or cease diligent prosecution,
maintenance and/or defense (which notice shall, in any event, be given no later than 60 days prior to the next deadline for any action that may be taken with respect to such Patent Right with the U.S. Patent & Trademark Office or any
foreign patent office), and, at Celladon’s request, Virovek shall consider in good faith permitting Celladon, at its expense, to prosecute, maintain and defend such Patent Right, such permission not to be unreasonably withheld. 

6.2 Infringement By Third Parties.Virovek and Celladon shall promptly notify the other in writing upon becoming
aware of any alleged or threatened infringement of any of the Patent Rights, where the infringing activity is competitive with the Services. Virovek shall have the first right to bring and control any action or proceeding with respect to any such
infringement at its own expense and by counsel of its own choice. If Virovek fails to bring any such action or proceeding within (a) 120 days following the notice of alleged infringement or (b) 30 days before the time limit, if
any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, or elects not to bring such action or proceeding, then Celladon shall have the right to bring and control any such action at its own
expense and by counsel of its own choice. In the event a party brings an infringement action in accordance with 

 
this Section 6.2, the other party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named as a party. Except as otherwise
agreed to by the parties as part of a cost-sharing arrangement, any recovery realized as a result of such litigation, after reimbursement of any litigation expenses of Virovek and Celladon, shall be retained by the party that brought and controlled
such litigation for purposes of this Agreement. 
 7. REPRESENTATIONS AND WARRANTIES 

7.1 Mutual Representations and Warranties. Each party represents and warrants to the other that, as of the
Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions
hereof; (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate
action; and (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it or its Affiliates is a party or by which it
or its Affiliates may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it or its Affiliates. 

7.2 Virovek Representations and Warranties. Virovek hereby represents and warrants to Celladon that: 

(a) Virovek has the full legal power, authority and right to grant the license under the Patent Rights and Trade Secrets
that it purports to grant hereunder, to transfer the Virovek Recombinant Baculoviruses and Trade Secrets to Celladon, to authorize the further transfer of the Virovek Recombinant Baculoviruses and Trade Secrets by Celladon to Affiliates and
sublicensees, and to perform its other obligations under this Agreement; 
 (b) neither the transfer of the Virovek
Recombinant Baculoviruses and Trade Secrets to Celladon, nor the further transfer of the Virovek Recombinant Baculoviruses and Trade Secrets by Celladon to Affiliates and sublicensees, conflicts with or would result in the breach or violation of the
terms of any agreement between Virovek and any Third Party; 
 (c) other than the license and sublicense granted
pursuant to Section 2.1, there are no licenses or other rights that are necessary for the transfer of the Virovek Recombinant Baculoviruses and Trade Secrets to Celladon, its Affiliates and its and their respective sublicensees or for the use
of the Virovek Recombinant Baculoviruses and Trade Secrets to develop and manufacture Celladon In Vitro Screening Reagent for use in the Field; 

(d) the use of the Virovek Recombinant Baculoviruses to develop and manufacture Celladon In Vitro Screening Reagent for
use in the Field does not infringe any issued patents of any Third Party and Virovek has not received any notice, and is not aware of any threat or claim, of infringement or misappropriation of any alleged rights asserted by any Third Party in
relation to the use of the Virovek Recombinant Baculoviruses or Trade Secrets; 

 (e) neither Virovek nor any of its Affiliates is a party to any legal
action, suit or proceeding relating to the Patent Rights, Trade Secrets or the Virovek Recombinant Baculoviruses; 

(f) Virovek has not received written notice concerning the institution or possible institution of any interference,
reexamination, reissue, revocation or nullification proceeding involving any Patent Rights; 
 (g) to Virovek’s
knowledge, the Patent Rights in existence on the Effective Date are not invalid or unenforceable, and Virovek is not aware of any patent controlled by a Third Party with claims that dominate (in whole or in part) the claims of the Patent Rights; and

 (h) during the term of this Agreement, neither Virovek nor any of its Affiliates shall enter into any agreement, or
take or fail to take any action, that would restrict Virovek’s legal right to grant to Celladon the rights and benefits contemplated under this Agreement. 

7.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES
OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING,
USAGE OR TRADE PRACTICES. 
 7.4 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 5,
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EACH PARTY’S PERFORMANCE OR LACK OF PERFORMANCE HEREUNDER OR ANY LICENSE GRANTED
HEREUNDER; provided, however, that this Section 7.4 shall not be construed to limit either party’s indemnification obligations under Article 9. 

8. TERM; TERMINATION 

8.1 Term. The term of this Agreement shall commence as of the Effective Date and, unless sooner terminated as provided
hereunder, shall continue until expiration of the last Royalty Term. Following the expiration of this Agreement, Celladon shall have a license on the same terms as set forth in Section 2.1, except that the license shall be fully-paid, royalty-free, irrevocable and perpetual. 
 8.2 Termination by Celladon.
Celladon may terminate this Agreement prior to its expiration at any time, for any reason or for no reason, upon 60 days’ prior written notice to Virovek. 

 8.3 Termination for Breach. Each party shall have the right to
terminate this Agreement upon 90 days’ prior written notice to the other upon or after the material breach of any material provision of this Agreement by the other party if the breaching party has not cured such breach within the 90-day
period following written notice of termination by the non-breaching party. 
 8.4 Effect of Termination. 

(a) Upon termination of this Agreement: 

(i) for breach by Virovek, the license granted under Section 2.1 shall be converted to a non-exclusive,
fully-paid, perpetual, irrevocable license and sublicense; 
 (ii) for any reason other than breach by Virovek, the
license granted under Section 2.1 shall terminate and be of no further force or effect; and 
 (iii) any
sublicenses granted under the license granted under Section 2.1 that are then in effect shall remain in full force and effect; provided that the sublicensee (A) is not then in material breach of its sublicense agreement and
(B) agrees to be bound to Virovek as a licensor under the terms and conditions of the sublicense agreement. 

(b) Within 30 days following the termination of this Agreement, each party shall return to the other party, or
destroy, upon the written request of the other party, any and all Confidential Information of the other party in its possession. 

(c) Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination. The provisions of Sections 4.4, 7.3, 7.4 and 8.4 and Articles 1, 5, 6, 9, 10 and 11 shall survive any termination or expiration of this Agreement. 

8.5 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Virovek are, and will
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The parties agree that Celladon, as
licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or
against Virovek under the U.S. Bankruptcy Code, Celladon will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not
already in its possession, will be promptly delivered to them (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Virovek elects to continue to perform all of its obligations under this Agreement,
or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of Virovek upon written request therefor by Celladon. 

 9. INDEMNIFICATION 

9.1 Indemnification by Celladon. Celladon hereby agrees to save, defend, indemnify and hold harmless Virovek, its
Affiliates and their respective officers, directors, employees, consultants and agents (the “Virovek Indemnitees”) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal
expense and attorneys’ fees (“Losses”), to which Virovek may become subject as a result of any claim, demand, action or other proceeding (“Claim”) by any Third Party to the extent such Losses
arise directly or indirectly out of (a) the gross negligence or willful misconduct of any Celladon Indemnitee (defined below), (b) the breach by Celladon of any warranty, representation, covenant or agreement made by Celladon in this
Agreement, or (c) the development, manufacture, use, handling, storage, sale or other disposition of Celladon In Vitro Screening Reagent, or the performance of Services, by Celladon, its Affiliates or sublicensees; in each case except to the
extent such Losses result from the gross negligence or willful misconduct of any Virovek Indemnitee or the breach by Virovek of any warranty, representation, covenant or agreement made by Virovek in this Agreement. 

9.2 Indemnification by Virovek. Virovek hereby agrees to save, defend, indemnify and hold harmless Celladon, its
Affiliates and their respective officers, directors, employees, consultants and agents (the “Celladon Indemnitees”) from and against any and all Losses to which Celladon may become subject as a result of any Claim by any
Third Party to the extent such Losses arise directly or indirectly out of (a) the gross negligence or willful misconduct of any Virovek Indemnitee, or (b) the breach by Virovek of any warranty, representation, covenant or agreement made by
Virovek in this Agreement, in each case except to the extent such Losses result from the gross negligence or willful misconduct of any Celladon Indemnitee or the breach by Celladon of any warranty, representation, covenant or agreement made by
Celladon in this Agreement. 
 9.3 Control of Defense. In the event a party seeks indemnification under
Section 9.1 or 9.2, it shall inform the other party (the “Indemnifying Party”) of a Claim as soon as reasonably practicable after it receives notice of the claim, shall permit the Indemnifying Party to
assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. 

10. DISPUTE RESOLUTION 

10.1 Dispute Resolution. Any dispute arising under or relating to the parties rights and obligations under this
Agreement will be referred to the Chief Executive Officers of Celladon and Virovek for resolution. In the event such officers are unable to resolve such dispute within 30 days or such dispute being referred to them, then, upon the written
request of either party to the other party, the dispute shall be subject to arbitration, as provided in Section 10.2. 

 10.2 Arbitration. 

(a) Claims. Subject to Section 10.3 below, any claim, dispute, or controversy of whatever nature arising out of or
relating to this Agreement that is not resolved under Section 10.1 within the applicable 30-day time period, including, without limitation, any action or claim based on tort, contract, or statute, or
concerning the interpretation, effect, termination, validity, performance and/or breach of this Agreement (“Claim”), shall be resolved by final and binding arbitration before a panel of three experts with relevant industry
experience (the “Arbitrators”). One Arbitrator shall be chosen by Celladon and one Arbitrator shall be chosen by Virovek within 15 days from the notice of initiation of arbitration. The third Arbitrator shall be chosen by
mutual agreement of the Arbitrator chosen by Celladon and the Arbitrator chosen by Virovek within 15 days of the date that the last of such Arbitrators were appointed. The arbitration shall be administered by the American Arbitration Association
(the “Administrator”) in accordance with its then existing arbitration rules or procedures regarding commercial or business disputes. The arbitration shall be held in San Diego, California. 

(b) Arbitrators’ Award. The Arbitrators shall, within 15 days after the conclusion of the arbitration
hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the Arbitrators shall be
final and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction. The Arbitrators shall be authorized to award compensatory damages, but shall NOT be authorized (i) to award
non-economic damages, such as for emotional distress, pain and suffering or loss of consortium, (ii) to award punitive damages, or (iii) to reform or modify this Agreement or any other agreements
contemplated hereunder; provided, however, that the damage limitations described in parts (i) and (ii) of this sentence will not apply if such damages are statutorily imposed. 

(c) Costs. Each party shall bear its own attorneys’ fees, costs, and disbursements arising out of the arbitration,
and shall pay an equal share of the fees and costs of the Arbitrators; provided, however, the Arbitrators shall be authorized to determine whether a party is the prevailing party, and if so, to award to that prevailing party reimbursement for
any or all of its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and/or the fees and costs of the Administrator and the Arbitrators. 

(d) Compliance with this Agreement. Unless the parties otherwise agree in writing, during the period of time that any
arbitration proceeding is pending under this Agreement, the parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of the pending arbitration proceeding. 

10.3 Court Actions. Nothing contained in this Agreement shall deny any party the right to seek injunctive or
other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding. In
addition, either 

 
party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of patents
or other proprietary or intellectual property rights, and no such dispute shall be subject to arbitration pursuant to Section 10.2. 
 11.
GENERAL PROVISIONS 
 11.1 Governing Law. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of California, excluding its conflicts of laws principles. 

11.2 Entire Agreement; Modification. This Agreement (including the Exhibit hereto) is both a final expression of the
parties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all
matters contained herein. This Agreement may not be modified or supplemented by any purchase order, change order, acknowledgment, order acceptance, standard terms of sale, invoice or the like. This Agreement may only be modified or supplemented in a
writing expressly stated for such purpose and signed by the parties to this Agreement. 
 11.3 Relationship Between the
Parties. The parties’ relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the parties. Neither
party is a legal representative of the other party, and neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever. 

11.4 Non-Waiver. The failure of a party to insist upon strict performance of any provision of this Agreement or to
exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a party of a particular
provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. 

11.5 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder
may be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld); provided, however, that either party may assign this Agreement and its rights
and obligations hereunder without the other party’s consent in connection with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock,
sale of assets or otherwise. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Agreement
shall be void. 

 11.6 No Third Party Beneficiaries. Except as expressly set forth in
Section 8.4, this Agreement is neither expressly nor impliedly made for the benefit of any party other than those executing it. 

11.7 Severability. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or
illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force
and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. 
 11.8
Notices. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile or electronic mail confirmed
thereafter by any of the foregoing, to the party to be notified at its address given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon
the earlier of: (a) the date of actual receipt; (b) if mailed, three business days after the date of postmark; or (c) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries. 

If to Celladon, notices must be addressed to: 

Celladon Corporation 

2223 Avenida de la Playa 

Suite 205 

La Jolla, CA 92037 

Attention: Chief Executive Officer 

Facsimile: (858) 964-0974 

If to Virovek, notices must be addressed to: 

Virovek Incorporation 

3521 Investment Blvd 

Suite 1 

Attention: Haifeng Chen 

Facsimile: 510-887-7178 

11.9 Force Majeure. Each party shall be excused from liability for the failure or delay in performance of any
obligation under this Agreement by reason of any event beyond such party’s reasonable control, including but not limited to, Acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, destruction or
other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other event similar to those enumerated above. Such excuse from liability shall be effective
only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused such event(s) to occur. Notice of a party’s failure or delay in performance due to force majeure must be
given to the other party within 10 days after its occurrence. All delivery dates under this Agreement that 

 
have been affected by force majeure shall be tolled for the duration of such force majeure. In no event shall any party be required to prevent or settle any labor disturbance or dispute. 

11.10 Interpretation. The headings of clauses contained in this Agreement preceding the text of the articles, sections,
subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the
singular shall include the plural where applicable, and all references to gender shall include both genders and the neuter. Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections, and
paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such sections; and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references
to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either party, irrespective of which party may be deemed to have caused the
ambiguity or uncertainty to exist. This Agreement has been prepared in the English language and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic,
oral or other communications between the parties regarding this Agreement shall be in the English language. 
 11.11
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one and the same instrument. 

 IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date first set forth above. 
  

									
	 CELLADON CORPORATION
	  		  	 VIROVEK INCORPORATION

					
	 By:
	 	 /s/ Rebecque J. Laba
	  		  	 By:
	  	 /s/ Haifeng Chen

	 Name: Rebecque J. Laba
	  		  	 Name: Haifeng Chen

	 Title: V.P. Finance & Admin
	  		  	 Title: CEO

 EXHIBIT A 

PATENT RIGHTS 
  

							
	 Application

Number
	  	 Publication

Number
	  	 Title
	  	 Filing

Date

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]

 ***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]